Diamond Therapeutics to present groundbreaking study at NIH event
Diamond Therapeutics to present groundbreaking study at NIH event News provided by Share this article Share this article Dr. Edward Sellers, head of Diamond's clinical advisory board, will speak about the benefits of low-dose psilocybin TORONTO, May 27, 2021 /PRNewswire/ - Diamond Therapeutics Inc. (" Diamond"), a leading psychedelic drug development company focused on sub-perceptual therapies for mental health, is pleased to announce that the head of its clinical advisory board, Dr. Edward Sellers, will be presenting at the NIH's Psilocybin Research Speaker Series on June 4, 2021. Dr. Selle...
Source: prnewswire.com